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IgG4-related disease (IgG4-RD) is a systemic illness including autoimmune pancreatitis 
and IgG4-related sclerosing cholangitis (IgG4-SC). Although hepatic presentation of 
IgG4-RD has been reported, whether intrahepatic small bile ducts and hepatocytes are 
direct targets of IgG4-RD is uncertain. IgG4-RD is pathologically characterized by the 
numerous IgG4+ cells found in affected organs, but this IgG4 positivity is also 
frequently found in extrahepatic cholangiocarcinoma and is prominent, albeit rarely, in 
other hepatobiliary diseases including primary sclerosing cholangitis and autoimmune 
hepatitis. Moreover, cholangiocarcinoma arising from precedent IgG4-SC and IgG4-SC 
accompanying precursor lesions of cholangiocarcinoma (biliary intraepithelial 
neoplasia) are also reported. Diagnostic criteria for IgG-RD and IgG4-SC were recently 
proposed, but each individual case should be diagnosed clinicopathologically on the 
basis of its individual features.  
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15.1 Introduction  
  IgG4-related disease (IgG4-RD) and its systemic nature were first described in 
Japan (1-5). IgG4-RD most profoundly affects the pancreas but involves most organs in 
the human body, including the pituitary gland, lacrimal glands, salivary glands, lungs, 
breast, bile duct, aorta, kidney, lymph nodes, retroperitoneum, and prostate. Initial or 
secondary presentation in the liver, skin, peripheral nerves, and gastrointestinal tract has 
also been reported. Infiltrates of numerous IgG4+ plasma cells in affected organs are 
important pathological findings of IgG4-RD. Obliterative phlebitis, storiform-type 
sclerosing fibrosis, and sometimes mass-forming type sclerosing fibrosis in the lung, 
pancreas, and liver are also characteristics of this disease. Regardless of the organ in 
which IgG4-RD develops, elevated serum IgG4 (≥135 mg/dL) and marked efficacy of 
steroid therapy are common characteristics. The prototype IgG4-RD disease is type I 
autoimmune pancreatitis (AIP). IgG4-related sclerosing cholangitis (IgG4-SC) involves 
sclerosing cholangitic lesions that arise as complications of AIP or, rarely, are isolated 
in the biliary tract system. IgG4-SC lesions share the characteristic features of AIP. 
Hepatic presentation of IgG4-RD has also been described in the literature (6-8); whether 
such disease is a primary liver manifestation or simply the extension of IgG4-SC into 
intrahepatic bile ducts is unclear. In this chapter, we summarize the present knowledge 
of IgG4-SC and several inflammatory and neoplastic hepatobiliary diseases 





  IgG4 is a minor immunoglobulin subtype composing 3%–6% of the total IgG 
circulating in adults (1). Systemic IgG4-RD features elevated serum IgG4 levels and 
abundant infiltration with IgG4+ plasma cells in affected organs (1, 9, 10). IgG4-SC can 
be viewed as a manifestation of IgG4-RD in the bile duct. In the differential diagnosis 
of IgG4-SC, primary sclerosing cholangitis (PSC, another prototype of sclerosing 
cholangitis), and cholangiocarcinoma are also clinicopathologically important. Each of 
these diseases requires an appropriate diagnosis and therapy, but their differentiation is 
not always easy. 
IgG4-SC exhibits severe inflammatory cell infiltrates containing abundant 
IgG4-bearing plasma cells and biliary sclerosis as a result of progressive fibrosis within 
the bile duct wall that leads to bile duct stenosis (Fig.1). These diffuse or localized 
sclerotic and stenotic lesions are found in the large bile ducts of the hepatic hilus, 
extrahepatic bile ducts, and, in some cases, the gall bladder. These biliary lesions show 
circumferential wall thickening and are prominent at stenotic sites. Similar 
inflammatory lesions are also common at non-stenotic biliary sites. IgG4-SC cases not 
involving other organs are rare; most cases are associated with AIP, particularly those 
with lesions in the intrapancreatic bile ducts. As with IgG4-RD in other organs, serum 
IgG4 values of IgG4-SC patients are usually elevated to ≥135 mg/dL, and the lesions 
are reversible and responsive to steroid therapy.  
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 Similar to the pancreatic ducts, the extrahepatic bile duct and gallbladder are covered 
by a single layer of epithelium and have peribiliary glands (11). Histologically, bile duct 
lesions in IgG4-SC resemble the inflammatory and sclerosing lesions found in the 
pancreatic duct of AIP. Characteristics of IgG4-SC lesions are as follows: 1) 
inflammation, mainly affecting the bile duct wall (chronic cholangitis) but also 
particularly prominent around peribiliary glands; the biliary epithelium is relatively 
preserved; 2) marked lymphoplasmacytic cell infiltration, fibrosis, and luminal stenosis 
in affected regions of the bile ducts; 3) storiform fibrosis, a characteristic of AIP, is 
observed in IgG4-SC cases with marked fibrosis; 4) numerous IgG4-bearing plasma 
cells, as revealed by immunohistochemical staining; and 5) obliterative phlebitis and 
perineural infiltration of IgG4+ cells (Fig.1). As seen in mass-forming pancreatitis, 
exacerbated inflammation from the hilum to the intrahepatic large bile duct can lead to 
inflammatory pseudotumors in the liver and hepatic hilus. Before the first report of 
IgG4-related AIPby Hamano et al. in 2001 (1), Nonomura et al. had reported in 1997 on 
a case of hepatic hilar inflammatory pseudotumor with cholangitis and phlebitis 
mimicking cholangiocarcinoma (12). We later confirmed that the lesions in this case 
were IgG4-related (Fig.2). At present, 2 types of inflammatory pseudotumors, 
fibrohistiocytic and lymphoplasmacytic, have been proposed. The latter is thought to be 
representative of IgG4-RD (13, 14).  
  As mentioned above, most IgG4-SC cases accompany IgG4-related AIP, but 
rare cases without the involvement of other organs are encountered. IgG4-SC cases 
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without pancreatic lesions are surely present. But whether the presence or absence of 
pancreatic lesions reflects differences in the pathological features of the IgG4 reaction 
in IgG4-SC or merely reflects differences in the pathological phenotype of systemic 
IgG4-RD is unclear. The characteristics of IgG4-SC not associated with pancreatic 
lesions have been described as follows (15, 16): 1) mainly affects middle-aged to 
elderly men; 2) serum IgG4 is normal or only slightly elevated in most cases; 3) cases 
with IgE and soluble IL-2 receptor elevation and antinuclear antibody+ status are 
frequent; 4) affected bile ducts show relatively long and flat narrowing, but peripheral 
bile duct stenosis is mild; and 5) affected bile ducts show marked IgG4+ plasmacytic 
cell infiltration. However, cases of IgG4-SC alone are clinically very hard to 
differentiate from biliary tumor, particularly cholangiocarcinoma. Although the cases of 
isolated IgG4-SC mainly display hilar biliary strictures, isolated intrapancreatic 
IgG4-SC is also reported (16). Of the five cases included in this report, all patients were 
male, with a mean age of 74.2 years. Bile duct wall thickening in lesions without 
luminal stenosis was detected using abdominal computed tomography in all the five 
cases. Interestingly, in three of the cases, serum IgG4 levels were within normal limits. 
The mean serum IgG4 level measured before surgery was 202.1 mg/dL (four cases). 
Isolated intrapancreatic IgG4-SC is difficult to diagnose, particularly if the IgG4 level 
remains normal (15, 17). Diagnostic criteria for IgG4-SC have been proposed by two 
groups in Research on Measures for Intractable Diseases supported by a Health Labour 
Sciences Research Grant in Japan. Characteristic and diagnostically-useful histological 
findings of bile duct tissue specimens include: 1) IgG4+ plasmacytic cell infiltration 
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(≥10/high power field (hpf); IgG4/IgG positive cell ratio of ≥40%); 2) marked 
lymphoplasmacytic cell infiltration and fibrosis, without neutrophil infiltration; 3) 
obliterative phlebitis or swirling fibrosis; and 4) storiform fibrosis. However, 
identification of these characteristics in small biopsy specimens obtained from the 
surface of the bile duct is difficult. Alternatively, the Diagnostic Criteria for AIP (the 
HISORt Criteria) proposed by the Mayo Clinic (18) have been applied to the diagnosis 
of IgG4-SC (19). These criteria emphasize IgG4+ plasmacytic cell infiltration, although 
abundant IgG4+ cell infiltration is important in the histology of IgG4-RD. Because the 
infiltration of IgG4+ cells is of varying degrees in the cases of cholangiocarcinoma 
described, care must be taken not to be overly influenced by diagnostic criteria that 
overemphasize IgG4+ cell infiltration in affected organs. Therefore, no single diagnostic 
criteria should be strictly followed; rather, each individual case should be 
clinicopathologically diagnosed on the basis of its own individual features. 
In the pathogenesis of IgG4-RD including IgG4-SC, the activation of the Th2 
immune response has been confirmed by several studies (20-24). Two regulatory 
cytokines, IL-10 and transforming growth factor-beta, are also significantly 
overexpressed in IgG4-RD (20). IL-10, a regulatory cytokine mainly produced by 
Foxp3+ regulatory T cells (Treg cells), Th2 cells, and IL-10-producing regulatory T 
cells, is thought to induce the differentiation of IgG4+ plasma cells and favor B-cell 
switching to IgG4 in the presence of IL-4 (25-27). In the presence of this cytokine 
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milieu, the induction of IgG4+ cells and fibrous sclerosing lesions could occur in other 
diseases and in coexisting inflammatory lesions in addition to IgG4-RD (28). 
 
15.3 Biliary distribution of IgG4+ cells in IgG4-SC 
 In IgG4-SC, numerous IgG4+ cells are found in the affected regions of bile 
ducts. These cells accompany other characteristic findings such as a predominance of 
IgG4+ cells among IgG+ cells and a unique pattern of sclerosing fibrosis. In addition, 
other regions of the biliary tree are affected. Therefore, biopsies from the Papilla of 
Vater to the peripheral intrahepatic small bile ducts, which are relative easily obtained, 
are useful for diagnosing IgG4-SC.  
Inflammation of the Papilla of Vater (papillitis) is commonly found in several 
inflammatory and neoplastic pancreatiobiliary diseases. Although duodenitis, including 
papillitis, is generally thought to be non-specific in IgG4-SC and AIP, papillitis 
accompanying IgG4+ plasmacytic cell infiltration is speculated to be an evidence of 
IgG4-SC and AIP (Fig.3). Moreover, the IgG4+ cell infiltration found in the papilla of 
Vater in IgG4-SC and AIP is severe compared with that of PSC, pancreatic cancer, and 




 Moreover, the site of the biliary tree opposite to the affected bile duct is also 
involved in IgG4-SC. Therefore, a liver needle biopsy obtained from the periphery of 
the liver is also useful for diagnosing IgG-SC and AIP (8). Closed pathological 
examination of partially hepatectomized or autopsied liver specimens reveals an 
infiltration of IgG4+ cells that are continuously and broadly distributed among 
intrahepatic bile ducts; IgG4+ cells are scattered in the small portal tracts containing the 
interlobular and septal bile ducts found in needle liver biopsies (Fig.4). Although 
intrahepatic small bile ducts as well as large bile ducts may be the target organs of 
IgG4-SC, the portal inflammation including IgG4+ cells is thought to result from IgG4+ 
cells spreading along the biliary tree from IgG4-SC lesions in the hepatic hilus. 
 
15.4 IgG4 hepatopathy 
Varying degrees of liver dysfunction are found in 50%–70% of patients with 
IgG4-related AIP (8, 30). Clinicopathological studies reveal an intrahepatic IgG4+ cell 
infiltration of ≥5/hpf in approximately 50% of AIP patients; the degree of infiltration 
correlates with serum IgG4 values (8, 30). A correlation is observed between 
parenchymal inflammation and AST values and between cholestasis and serum bilirubin 
levels. The hepatic lesions observed in AIP patients are known as IgG4-hepatopathy (8). 
Whether the pathogenesis of IgG4-RD, including IgG4-SC, involves an autoimmune 
response, and whether hepatic parenchymal cells such as hepatocytes and 
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cholangiocytes of intrahepatic small bile ducts are target organs of IgG4-RD are 
unknown. However, the serum IgG4 levels and the incidence of IgG4-bearing cells in 
affected organs is higher in patients with IgG4-RD than in patients with other 
autoimmune-mediated liver diseases such as AIH, primary biliary cirrhosis (PBC), and 
PSC (8). On pathological analysis, liver biopsy specimens from patients with AIP reveal 
a marked infiltration of inflammatory cells, including IgG4+ plasma cells, in small 
intrahepatic portal tracts (5, 8, 31). Umemura et al. (8) specifically surveyed the 
histology of liver biopsies from patients with AIP to clarify the pathogenesis of clinical 
liver injury, noting 5 intrahepatic histological patterns: portal inflammation, large bile 
duct damage, portal sclerosis, lobular hepatitis, and cholestasis (Fig.5). Multiple 
histological patterns were found to coexist. The portal inflammation pattern consists of 
an intense infiltration of mononuclear cells containing plasma cells, with or without 
interface hepatitis. If these intrahepatic findings are isolated in the liver without 
IgG4-SC, they are presumed to be a liver manifestation of IgG-RD in AIP patients. In 
contrast, if the histological lesions of IgG4-SC are always present in AIP patients, 
despite the absence of clinical or radiological findings, all intrahepatic findings 
identified in AIP patients can be considered secondary to extrahepatic bile duct damage 
associated with IgG4-SC. Portal inflammation may be involved in IgG4-SC, causing the 
progression of periductal inflammation along the biliary tracts and the smaller tracts 
encountered in needle liver biopsies. Moreover, based on our experience of patients 
with serum IgG4 >1000 mg/dL, interface hepatitis and hepatitis-associated bile duct 
injury are also found, suggesting a correlation between the severity of inflammation in 
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the affected extrahepatic bile ducts and the degree of inflammatory extension along 
intrahepatic bile ducts. The pattern of large bile duct damage is characterized by 
ductular proliferation, neutrophil infiltration, and edematous change in the portal areas. 
These findings are well known to occur secondarily to stenosis and the obstruction of 
extrahepatic bile duct, irrespective of any biliary diseases. The portal sclerosis pattern is 
consistent with dense fibrosis. In general, portal inflammation is scarce in sclerotic 
portal tracts; however, the sclerotic change may be just a remnant of portal 
inflammation after the active inflammation subsides, and/or secondary portal tract 
fibrosis may be associated with sclerosing cholangitis involving the large or 
extrahepatic bile ducts. The lobular hepatitis pattern may resemble that of viral hepatitis. 
Pathology reveals a parenchymal inflammation pattern in conjunction with 
hepatocellular focal necrosis in the parenchyma. Mild parenchymal inflammation is 
observed in a variety of biliary diseases and is thought to be caused by cholestasis as a 
non-specific reactive change. The cholestatic pattern is a canalicular cholestasis found 
predominantly in the centrilobular area and is consistent with extensive stenosis and 
obstruction of the affected extrahepatic bile ducts, including intrapancreatic bile ducts. 
Although the combined findings of parenchymal inflammation (lobular hepatitis) and 
portal inflammation with an interface hepatitis may indicate a primary liver 
manifestation (32), all five pathological findings could be explained as secondary to 
sclerosing cholangitis or obstruction of the extrahepatic biliary tract and may not be 
specifically related to the histopathogenesis of IgG4-RD.  
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The liver-related manifestations of IgG4-RD are heterogeneous and not well 
described within the literature (8, 32, 33). Whether IgG4-hepatopathy is a primary liver 
manifestation of systemic IgG4-RD or an excess of IgG4+ cells along the biliary tract 
due to IgG4-SC is unknown. However, IgG4-hepatopathy is an important finding for 
the diagnosis of IgG4-RD. Diagnosing IgG4-SC in the setting of AIP can be 
accomplished using the diagnostic criteria for AIP. In cases of IgG4-SC without 
pancreatic lesions, the presence or absence of IgG4-hepatopathy may be useful to 
differentiate it from conditions such as PSC and cholangiocarcinoma. 
 
15.5 IgG4-associated autoimmune hepatitis  
  Elevated serum IgG4 levels have been reported in several patients diagnosed with 
AIH (6, 7, 34). IgG4-associated AIH is an identified disease entity characterized by 
definitive AIH according to the International Autoimmune Hepatitis Group (IAIHG) 
scoring system (35) and the histopathological features of IgG4-RD. IgG4-associated de 
novo AIH after liver transplantation has also been reported (36). In a survey of 60 
patients with type 1 AIH, Umemura et al. reported that 2 out of 60 (3.3%) showed 
features suggesting IgG4-RD, with elevated serum IgG4 (≥135 mg/dL) and increased 
IgG4 positive cells in the portal tracts (≥10/hpf); however, liver histology indicated 
chronic active hepatitis accompanied by liver cell rosette formation, indistinguishable 
from classic AIH (7). Bile duct injury and cholestasis found in IgG4-hepatopathy, as 
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mentioned above, were not prominent in these two cases of IgG4-associated AIH (7). 
Additionally, Chung et al. (37) reported in a study of 26 AIH patients that AIH can be 
classified as either IgG4-associated or non–IgG4-associated. IgG4-associated AIH is 
characterized by higher infiltration of CD3+ T cells, CD20+ B cells, CD38+ plasma cells, 
and IgG+ cells as well as IgG4+ cells in the liver. In contrast to classic AIH, these 
IgG4-associated AIH cases showed a marked response to prednisolone therapy, with 
improvements in serum IgG4 values, liver function, and liver histology (6, 36, 37). 
Some patients developed IgG4-SC during follow-up observation, and others had IgG4+ 
cell infiltration in both the liver and the gallbladder (6). The scoring system of the 
International AIH Group has been widely used to diagnose AIH. Simplified criteria 
were adopted in 2008 (38), using parameters including autoantibodies, serum IgG 
values, hepatitis viruses, and pathological hepatic findings of lymphoplasmacytic cell 
infiltration in the portal tracts, interface hepatitis, hepatocytic rosette formation, and 
emperipolesis. On the basis of these simplified criteria, most IgG4-associated AIH cases 
are likely diagnosed as definite AIH. For both AIH diseases, regardless of the presence 
or absence of prominent IgG4+ cells, immunosuppression with steroids is the mainstay 
of therapy. Future studies are needed to determine the significance and importance of 




15.6 Overlap syndrome of IgG4-SC and PBC 
PBC mainly affects middle-aged females. Histologically, the interlobular bile 
ducts are damaged and show characteristic findings of chronic nonsuppurative 
destructive cholangitis followed by progressive bile duct loss via apoptosis (39-41). 
Serologically, the presence of autoantibodies (antimitochondrial antibody (AMA) and 
anti-M2 antibody) is a specific indicator of PBC. The major proteins recognized by 
AMA are subunits of the 2-oxo acid dehydrogenase complexes, including the E2 
components of the pyruvate dehydrogenase complex (PDC), the 2-oxo-glutarate 
dehydrogenase complex, the branched-chain 2-oxo acid dehydrogenase complex, and 
the E3 binding protein (E3BP or Protein X) (42). The etiopathogenesis of PBC remains 
speculative, but the cross-reaction of human and bacterial PDC-E2 with AMA and 
autoreactive T cells in PBC patients suspects the association of molecular mimicry in 
the pathogenesis of PBC (43-45).  CD4+ helper T cells are essential regulators of 
immune responses and inflammatory diseases. Immunoreactivity to intra- and 
extracellular antigens is primarily regulated by two different types of memory CD4+ 
helper T cells. These Th1 and Th2 cells are principally distinguished by their production 
of different cytokines as well as their ability to induce either cellular (Th1) or humoral 
(Th2) immune reactions. Most studies on the Th1/Th2 balance in liver diseases have 
been based on the profile of cytokines using peripheral blood lymphocytes or liver 
tissues; such studies have classified PBC as a Th1-predominant disease (41, 46-48).  
Harada -15- 
 
Whereas IgG4-SC is associated with systemic IgG4-RD diseases such as AIP, 
PBC is associated with a variety of autoimmune diseases, irrespective of liver 
involvement, such as AIH, Sjogren syndrome, rheumatoid arthritis, and Hashimoto 
thyroiditis. Although seemingly inconsistent, four cases of concurrent IgG4-RD and 
PBC have been reported (49-52). Two of these cases involved PBC and AIP, with 
elevated serum IgG4 and AMA positivity. One of these cases involved IgG4-SC (49, 
50) in a 65-year-old male. In this case, the pathological lesions of PBC and IgG4-SC are 
speculated to affect the intrahepatic small bile ducts and the large bile ducts of the 
hepatic hilus, respectively (50). Moreover, unique overlap cases of isolated IgG4-SC 
without any other IgG4-RD lesions and of PBC have been reported (51, 52). Although 
IgG4-SC and PBC commonly affect older men and middle-aged women, respectively, 
these overlap cases involved a 61- and a 45-year-old man(51, 52). Figure 6 shows the 
case of 61-year-old man.(52)  
With respect to PBC, these patients are not typical, though approximately 15% 
of PBC patients are male (53, 54). Because PBC differs from IgG4-associated AIH as 
described above, the occurrence of PBC is unlikely to be related to IgG4-RD. In 
addition, the cytokine milieu differs between PBC (Th1) and IgG4-RD (Th2) (20, 55, 
56). The concomitance of the two diseases associated with opposing cytokine networks 
is unique. By one interpretation, PBC and IgG4-SC affect bile ducts at different 
anatomical levels; thus, the peripheral intrahepatic small bile ducts (PBC) and 
extrahepatic bile ducts (IgG4-SC) are damaged by different mechanisms. However, Li 
Harada -16- 
 
et al. (50) speculate that according to the systemic nature of AIP and PBC, the 
coexistence of AIP and PBC is not a coincidence. Review of the pathogenesis of both 
diseases reveals several common features, including genetic susceptibility conferred by 
HLA-DQB1 (57, 58), dysregulation of cytotoxic T-lymphocyte antigen-4, T-cell 
mediated pathogenesis (59, 60), and the involvement of B cells associated with 
circulating autoantibodies and infiltration of plasma cells (59, 61-63). The association 
between the pathogenesis of IgG4-RD and PBC has not been further elucidated. 
Successful treatment of concomitant disease requires combination therapy with  
prednisolone for the IgG4-SC and ursodeoxycholic acid for the PBC (51). 
Elevated serum IgG subclasses are associated with numerous autoimmune 
diseases, including primary Sjogren syndrome, systemic sclerosis, systemic lupus 
erythematosus, and PBC (64). Serum IgG1 (IgG1/IgG) and/or IgG3 (IgG3/IgG) are 
significantly increased in these autoimmune diseases, with serum IgG subclass levels 
presenting distinct patterns in different autoimmune diseases. For IgG4-RD, 6.34% of 
patients have serum IgG4 >135 mg/dL, but there are no significant differences in the 
frequency of elevated serum IgG4 levels between patients and healthy controls. We 
should reconsider the pathological significance of increased serum IgG4 levels. Further 
studies of serum IgG subclass distribution will help to elucidate the 




15.7 Cholangiocarcinoma with histological IgG4 positivity 
Differentiating between IgG4-SC and cholangiocarcinoma is clinically 
important but very difficult, even with the use of recent modalities. The infiltration of 
IgG4+ cells is very characteristic and useful in the diagnosis of IgG4-RD, but 
histological IgG4 positivity is found in several other inflammatory and neoplastic 
lesions, including PSC (24, 65). Moreover, patients with pancreatic adenocarcinoma 
accompanied by histological IgG4 positivity and/or elevated serum IgG4 levels (66-69) 
and those with pancreatic and biliary cancers arising from IgG4-RD (68, 70, 71) have 
been reported. However, a cause-and-effect relationship between histological IgG4 
positivity and these cancers has not been demonstrated. Our retrospective survey (72) of 
68 surgical specimens from patients with extrahepatic biliary cancers including 
common bile duct cancers, gallbladder cancer, and cancers of the papilla of Vater 
reports that 10 or more IgG4+ cells/hpf were observed in 37% of cases. Cases 
resembling IgG4-RD and having marked infiltration (≥50 IgG4+ cells/hpf) made up 9% 
of the total (Fig.7). In contrast, intrahepatic bile ducts and hepatocellular carcinoma 
mostly lack the prominent IgG4+ cells (unpublished data), although the reason is 
unknown. IgG4+ cells are found within and around the tumor area, predominantly in the 
invasive front of the carcinoma tissue. Therefore, the presence of IgG4+ cells is not a 
histological hallmark of IgG4-RD, and histological IgG4 positivity is speculated to 
occur non-specifically in carcinoma tissues (72). Several cancers involving remarkable 
infiltration of IgG4+ cells (≥50 cells/hpf) are speculated to originate from precedent 
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IgG4-SC, but data collected before the diagnosis of each cancer is needed to 
demonstrate the presence of IgG4-SC. 
Patients with IgG4-SC are generally older men (85%) (19), but this male 
preponderance is not found in histological IgG4 positivity concomitant with 
cholangiocarcinoma according to our survey (72). As a histological characteristic of 
cholangiocarcinoma, irrespective of intra- vs. extrahepatic location, desmoplastic 
change consisting of fibrosis occurs. However, storiform fibrosis and obliterative 
phlebitis, other characteristics of IgG4-RD, are not prominent in cholangiocarcinoma. 
These observations indicate that IgG4-SC and cholangiocarcinoma share features, 
including increased fibrosis and histological IgG4 positivity, but the pathogenetic 
mechanisms underlying these features are speculated to differ.   
The expression of the Th2-type cytokine milieu and IL-10 produced by Treg 
cells is assumed to involve IgG4 class switching and/or the progressive 
proliferation/differentiation of IgG4+ plasma cells (20, 24, 26, 73, 74). The induction of 
IgG4+ cells is directly regulated by IL-10 (25). This known regulatory/inhibitory 
cytokine plays the main role in the inhibition of the general immune reaction and 
possibly in IgG4-RD. The clinicopathological significance of histological IgG4 
positivity in biliary tract cancers is still unknown, but our studies suggest that IgG4 
positivity in cancer reflects the immune escape from cancer immunity (28, 72). In fact, 
the degree of IgG4+ infiltration in biliary tract cancers correlates with the degree of 
CD8+ cytotoxic T cell invasion into cancer cell layers (72). Moreover, patients with 
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IgG4-rich tissues in biliary tract cancers have a poor prognosis compared with those 
having IgG4-poor tissues (72). Because the cancer cells as well as Treg cells produce 
IL-10, the cancer cells themselves take part in the IL10-induced milieu (28).  
In biliary cancers, IgG4+ cells are not only found in cancer nests but are also 
scattered in the non-neoplastic biliary mucosa adjacent to the cancerous mucosa (75, 76). 
As shown in Fig. 8, many IgG4+ cells are found within and peripheral to the invasive 
regions of submucosal layers. A similar IgG4 positivity is prominent in the 
non-neoplastic mucosa around the primary cancer lesion. Although a biopsy of the bile 
duct is the best modality for diagnosing cholangiocarcinoma, such examination is 
unfortunately limited in the superficial biliary mucosa using biopsy specimens. 
Therefore, if a biopsy specimen is obtained from this IgG4-rich, non-neoplastic biliary 
mucosa in patients with increased serum IgG4 levels, the condition could be diagnosed 
as “cholangitis with IgG4+ cells, consistent with IgG4-SC.” Another informative case 
involves that of a 70-year-old male with serum IgG4 of 113 mg/dL, the borderline zone 
for IgG4-RD. Radiologically, IgG4-SC, PSC, and cholangiocarcinoma of the hepatic 
hilus were included in the differential diagnosis. Cytologically, no atypical cells were 
detected in bile specimens. Biopsies of the Ampulla of Vater and liver revealed 
infiltration of numerous IgG4+ cells (Fig.9), consistent with IgG4-SC. However, the 
biopsy of the stenotic biliary region indicated the presence of adenocarcinoma 
(cholangiocarcinoma) (Fig.9). The bile duct biopsy from the stenotic region is the 
cornerstone of differential diagnosis; the pathological diagnosis of cancer is very easy in 
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appropriate specimens. This case emphasizes the importance of using appropriate 
specimens for pathological diagnosis and understanding the distribution of IgG4+ cells 
in cholangiocarcinoma. That is, histological IgG4 positivity is not only localized in and 
around the primary cancer but also broadly distributed into the distal and proximal 
regions of the biliary tree. Although few in number, cholangiocarcinoma cases arising 
from preceding IgG4-SC have been reported (68, 70, 71); in addition, the precursor 
lesions of cholangiocarcinoma (BilIN lesions) are often encountered in IgG4-SC 
(Fig.10) (77). Therefore, in practice, it is impossible to completely exclude the 
possibility of cholangiocarcinoma in the diagnosis of IgG4-SC. Elevated serum IgG4 
values are an important finding when diagnosing AIP and IgG4-SC, but are not 
sufficient to definitively diagnose IgG4-RD. Rather, a danger lurks that IgG4-RD may 
be diagnosed or excluded too readily, and serum IgG4 values should not be regarded as 
more than an adjuvant diagnostic clue.  
 
15.8 Concluding remarks 
IgG4-RD is a systemic disease that affects most organs. Most patients 
synchronously or metachronously suffer from multiple organ involvement. AIP is the 
prototype of IgG4-RD, and extrahepatic biliary tracts, including the gall bladder, are 
also surely a manifestation of IgG4-RD. However, whether intrahepatic small bile ducts 
and hepatocytes are direct targets in IgG4-RD is unknown. Moreover, an increase in 
Harada -21- 
 
IgG4+ cells is highly sensitive but not highly specific for IgG4-DR. In contrast, several 
cases of IgG4-RD with low serum IgG4 levels and/or scant IgG4+ cell infiltration in 
target organs have also been reported. Although IgG4-related lesions present numerous 
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Figure 1. Representative IgG4-related sclerosing cholangitis (IgG4-SC) associated with 
autoimmune pancreatitis (AIP). A and B: Macroscopic and semi-macroscopic findings, 
respectively. Arrows and arrowheads denote the stenotic bile duct and pancreatic duct 
with wall thickening, respectively. C: Inflammation and edema are found in the 
fibrous-thickened wall and are particularly prominent around the peribiliary gland 
(arrows). The mucosa is relatively preserved, with scant inflammation. D: Higher 
magnification of inflammatory area. Many scattered plasma cells and eosinophils are 
seen. E: Immunohistochemistry for IgG4. Abundant positive plasma cells are seen. F: 
Storiform fibrosis and perineural inflammation (arrow) are prominent.  
  
Figure 2. Inflammatory pseudotumor with many IgG4+ liver cells. A: Semi-macroscopic 
findings. Fibrous nodule (arrow) is seen. B: Nodule consists of typical storiform fibrosis 
and inflammation. C: Chronic cholangitis in adjacent portal tract.  
 
Figure 3. Inflammation of Papilla of Vater (papillitis) in IgG4-related sclerosing 
cholangitis (IgG4-SC) associated with autoimmune pancreatitis (AIP). A: Inflammation 
is prominent, but differentiating between non-specific and IgG4-related papillitis is 
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difficult. B: Immunohistochemistry for IgG4 reveals the presence of many IgG4+ cells 
and IgG4 deposition in the stroma and on epithelial cells.  
 
Figure 4. Autopsied live specimens of systemic IgG4-related disease with IgG4-related 
sclerosing cholangitis. A: In subcapsular area of liver, mild to moderately inflamed 
portal tracts (arrows) are seen. B: Portal tract is mildly sclerotic and a minor scattering 
of inflammatory cells is seen. C: Immunohistochemistry for IgG4. Many positive cells 
are found within portal tracts.  
 
Figure 5. Representative findings of IgG4-hepatopathy. A: Prominent portal 
inflammation with interface hepatitis (arrow). B: Inflamed portal tracts contain many 
IgG4+ cells. Immunohistochemistry for IgG4. C: Lobular hepatitis. Some focal necroses 
are found (arrows). D: Canalicular cholestasis. Bile plugs are found in dilated bile 
canaliculi (arrows). 
 
Figure 6. Overlap syndrome of IgG4-related sclerosing cholangitis and primary biliary 
cirrhosis (PBC) in a 61-year-old man. A: In inflamed portal tracts, moderate 
inflammatory cell infiltrate, and chronic, nonsuppurative destructive cholangitis 
(CNSDC, arrow) are seen. B: Immunohistochemistry for IgG4. Many positive cells are 
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seen. Their distribution is mainly in the peripheral portal tract, but scant cells are 
located around CNSDC.  
 
Figure 7. Extrahepatic cholangiocarcinoma. A: Primary carcinoma nest consists of 
adenocarcinoma with abundant inflammatory cells. B: Immunohistochemistry for IgG4 
reveals the presence of many IgG4+ cells within cancer nests.  
 
Figure 8. Gall bladder cancer. A: Section adjacent to the primary cancer area, but a 
cancer nest (T) invades the subserosal layer with marked inflammatory cells. 
Non-neoplastic surface mucosa (M) also accompanies inflammation. B and C: 
Immunohistochemistry for IgG4. In the cancerous region (B) and the non-neoplastic 
superficial mucosa (C), many IgG4+ cells are intermixed with inflammatory infiltrate. 
 
Figure 9. Cholangiocarcinoma of the hepatic hilus accompanying IgG4 positivity in the 
Ampulla of Vater and peripheral liver. A. Biopsy of the Ampulla of Vater. 
Immunohistochemistry for IgG4 demonstrates the presence of several positive cells 
within papillitis. B and C: Liver needle biopsy. Mild portal inflammation (B) and 
several IgG4+ cells (C) are found in peripheral small portal tracts. D: Biopsy from the 
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stenotic large bile duct in the hepatic hilus. Well- (arrow) and poorly (arrowhead) 
differentiated adenocarcinomas (cholangiocarcinoma) are present.  
 
Figure 10. IgG4-related sclerosing cholangitis affecting the common bile duct. A: 
Biliary intraepithelial neoplasia (BilIN) is found in the preserved biliary epithelium 
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